What is IMNM's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 2.31B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for IMNM?

P/E (TTM) is n/a and 52-week range is $13.49 to $30.06 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s IMNM figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for IMNM?

The company profile lists revenue (TTM) near $13M, net income (TTM) near $-21.30B, EPS (TTM) near $-2.51 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Immunome Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Bothell, Washington, US, 113.3M shares outstanding, ISIN US45257U1088 when available from company profile and filing metadata.

Immunome Inc

$IMNM

Health Care · Biotechnology

IR Run Scenarios

$19.55

+1.24%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. The company is headquartered in Bothell, Washington and currently employs 117 full-time employees. The company went IPO on 2020-10-02. The firm is engaged in advancing an innovative portfolio of therapeutics in the design, development, and commercialization of targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Its advanced pipeline programs are varegacestat, a gamma secretase inhibitor which is in a Phase III trial for the treatment of desmoid tumors; IM-1021, an ROR1-targeted ADC which is in a Phase I trial, and IM-3050, a FAP-targeted radioligand. The firm's pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. IM-1617 is a potential first-in-class ADC that targets an undisclosed receptor that is expressed in a range of solid tumors, including colorectal cancer and ovarian cancers.

Employees

117

Website

immunome.com/

IPO

2020-10-02

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)